Bristol Myers Squibb will acquire radiopharmaceutical therapeutics company RayzeBio for $62.50 a share in cash. Continue reading this article with a Barron’s subscription. View Options Source link
Read more Bristol Myers to Acquire RayzeBio in Deal Valued at $4.1 BillionBy Anthony O. Goriainoff AstraZeneca said Thursday that its and MSD’s Lynparza cancer treatment had been approved in the U.S. for the treatment of metastatic castration-resistant prostate cancer,…
Read more AstraZeneca Says US Approved Lynparza as a Prostate Cancer TreatmentNearly two years after biotechnology stocks began to tumble, executives at small and midsize companies in the space are finally accepting that share prices aren’t bouncing back anytime…
Read more Tanking Biotech Stocks Will Mean a Big Year for Deals. Who Could Benefit.By Joe Hoppe AstraZeneca PLC said Monday that it has agreed to buy CinCor Pharma, Inc., acquiring global rights to the latter’s baxdrostat cardiorenal drug for an upfront…
Read more AstraZeneca PLC Will Buy CinCor for Cardiorenal Asset
